Mangrove Partners Invests $17.05 Million in iShares Biotechnology ETF (NASDAQ:IBB)
Mangrove Partners acquired a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 134,281 shares of the financial services provider’s stock, valued at approximately $17,048,000. iShares Biotechnology ETF comprises approximately 1.2% of Mangrove Partners’ holdings, making the stock its 28th biggest position. Mangrove Partners owned about 0.23% of iShares Biotechnology ETF as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also modified their holdings of the company. WealthPLAN Partners LLC acquired a new position in iShares Biotechnology ETF during the 1st quarter valued at $27,000. CoreFirst Bank & Trust acquired a new position in iShares Biotechnology ETF during the 2nd quarter valued at $30,000. Archer Investment Corp acquired a new position in iShares Biotechnology ETF during the 2nd quarter valued at $48,000. Newbridge Financial Services Group Inc. raised its stake in iShares Biotechnology ETF by 27.6% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 388 shares of the financial services provider’s stock valued at $49,000 after purchasing an additional 84 shares during the last quarter. Finally, Crewe Advisors LLC acquired a new position in iShares Biotechnology ETF during the 1st quarter valued at $51,000. 69.61% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Trading Up 1.4 %
iShares Biotechnology ETF stock traded up $1.67 on Friday, hitting $122.60. The company’s stock had a trading volume of 1,645,806 shares, compared to its average volume of 1,787,018. The company has a fifty day moving average price of $119.01 and a 200-day moving average price of $124.89. iShares Biotechnology ETF has a one year low of $111.83 and a one year high of $138.74.
iShares Biotechnology ETF Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, October 2nd. Shareholders of record on Wednesday, September 27th were issued a $0.1532 dividend. This represents a $0.61 annualized dividend and a yield of 0.50%. The ex-dividend date was Tuesday, September 26th.
iShares Biotechnology ETF Company Profile (Free Report)
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider iShares Biotechnology ETF, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and iShares Biotechnology ETF wasn’t on the list.
While iShares Biotechnology ETF currently has a “hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.